BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Daniel PV, Dogra S, Rawat P, Choubey A, Khan AS, Rajak S, Kamthan M, Mondal P. NF-κB p65 regulates hepatic lipogenesis by promoting nuclear entry of ChREBP in response to a high carbohydrate diet. J Biol Chem 2021;296:100714. [PMID: 33930463 DOI: 10.1016/j.jbc.2021.100714] [Reference Citation Analysis]
2 Dikariyanto V, Smith L, Francis L, Robertson M, Kusaslan E, O'Callaghan-Latham M, Palanche C, D'Annibale M, Christodoulou D, Basty N, Whitcher B, Shuaib H, Charles-Edwards G, Chowienczyk PJ, Ellis PR, Berry SEE, Hall WL. Snacking on whole almonds for 6 weeks improves endothelial function and lowers LDL cholesterol but does not affect liver fat and other cardiometabolic risk factors in healthy adults: the ATTIS study, a randomized controlled trial. Am J Clin Nutr 2020;111:1178-89. [PMID: 32412597 DOI: 10.1093/ajcn/nqaa100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
3 Peláez-Jaramillo MJ, Cárdenas-Mojica AA, Gaete PV, Mendivil CO. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. Diabetes Ther 2018;9:521-43. [PMID: 29411291 DOI: 10.1007/s13300-018-0374-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
4 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349-360. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in Crossref: 172] [Cited by in F6Publishing: 150] [Article Influence: 57.3] [Reference Citation Analysis]
5 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 Li Z, Zhou Z, Hu L, Deng L, Ren Q, Zhang L. ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis. Pharmacol Res 2020;159:105035. [PMID: 32562818 DOI: 10.1016/j.phrs.2020.105035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23(36): 6549-6570 [PMID: 29085205 DOI: 10.3748/wjg.v23.i36.6549] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 63] [Article Influence: 20.3] [Reference Citation Analysis]
8 Orchard TJ, Cariou B, Connelly MA, Otvos JD, Zhang S, Antalis CJ, Ivanyi T, Hoogwerf BJ. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes. Cardiovasc Diabetol 2017;16:73. [PMID: 28587667 DOI: 10.1186/s12933-017-0555-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chen BB, Han Y, Pan X, Yan J, Liu W, Li Y, Lin X, Xu S, Peng XE. Association between nut intake and non-alcoholic fatty liver disease risk: a retrospective case-control study in a sample of Chinese Han adults. BMJ Open 2019;9:e028961. [PMID: 31488477 DOI: 10.1136/bmjopen-2019-028961] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
10 Farshadpour F, Taherkhani R, Ravanbod MR, Eghbali SS. Prevalence and Genotype Distribution of Hepatitis C Virus Infection among Patients with Type 2 Diabetes Mellitus. Med Princ Pract 2018;27:308-16. [PMID: 29621783 DOI: 10.1159/000488985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
11 Khurmi NS, Chang Y, Eric Steidley D, Singer AL, Hewitt WR, Reddy KS, Moss AA, Mathur AK. Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States: Liver Transplantation. Liver Transpl 2018;24:1398-410. [DOI: 10.1002/lt.25055] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
12 Lonardo A, Ballestri S, Targher G. “ Not all forms of NAFLD were created equal ”. Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis? Atherosclerosis 2017;257:253-5. [DOI: 10.1016/j.atherosclerosis.2017.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
13 Di Stasi V, Maseroli E, Rastrelli G, Scavello I, Cipriani S, Todisco T, Marchiani S, Sorbi F, Fambrini M, Petraglia F, Maggi M, Vignozzi L. SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction. Front Endocrinol (Lausanne). 2021;12:641446. [PMID: 33854482 DOI: 10.3389/fendo.2021.641446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Trovato GM. Non-alcoholic fatty liver disease and Atherosclerosis at a crossroad: The overlap of a theory of change and bioinformatics. World J Gastrointest Pathophysiol 2020; 11(3): 57-63 [PMID: 32435522 DOI: 10.4291/wjgp.v11.i3.57] [Reference Citation Analysis]
15 Kawaguchi T, Koga H, Torimura T. Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. Curr Hepatology Rep 2017;16:317-25. [DOI: 10.1007/s11901-017-0370-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361-371. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 53.7] [Reference Citation Analysis]
17 Curran A, Rull A, Navarro J, Vidal-González J, Martin-Castillo M, Burgos J, Falcó V, Ribera E, Torrella A, Planas B, Peraire J, Crespo M. Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. J Clin Med 2020;9:E1246. [PMID: 32344934 DOI: 10.3390/jcm9051246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hoyles L, Fernández-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez-Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Foufelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R, Dumas ME. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 2018;24:1070-80. [PMID: 29942096 DOI: 10.1038/s41591-018-0061-3] [Cited by in Crossref: 214] [Cited by in F6Publishing: 192] [Article Influence: 71.3] [Reference Citation Analysis]
19 Dibba P, Cholankeril R, Li AA, Patel M, Fayek M, Dibble C, Okpara N, Hines A, Ahmed A. Hepatitis C in Pregnancy. Diseases 2018;6:E31. [PMID: 29702563 DOI: 10.3390/diseases6020031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
20 Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. Dig Liver Dis 2019;51:142-8. [PMID: 30076015 DOI: 10.1016/j.dld.2018.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Joo HW, Song YS, Park IH, Shen GY, Seong JH, Shin NK, Lee AH, Kim H, Kim KS. Granulocyte Colony Stimulating Factor Ameliorates Hepatic Steatosis Associated with Improvement of Autophagy in Diabetic Rats. Can J Gastroenterol Hepatol 2020;2020:2156829. [PMID: 32775312 DOI: 10.1155/2020/2156829] [Reference Citation Analysis]
22 Kazeminasab F, Marandi SM, Baharlooie M, Nasr-Esfahani MH, Ghaedi K. Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice. Nutr Metab (Lond) 2021;18:75. [PMID: 34284789 DOI: 10.1186/s12986-021-00600-0] [Reference Citation Analysis]
23 Crakes KR, Santos Rocha C, Grishina I, Hirao LA, Napoli E, Gaulke CA, Fenton A, Datta S, Arredondo J, Marco ML, Sankaran-Walters S, Cortopassi G, Giulivi C, Dandekar S. PPARα-targeted mitochondrial bioenergetics mediate repair of intestinal barriers at the host-microbe intersection during SIV infection. Proc Natl Acad Sci U S A 2019;116:24819-29. [PMID: 31740620 DOI: 10.1073/pnas.1908977116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
24 Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71:793-801. [PMID: 31279902 DOI: 10.1016/j.jhep.2019.06.021] [Cited by in Crossref: 295] [Cited by in F6Publishing: 276] [Article Influence: 147.5] [Reference Citation Analysis]
25 Tirosh O. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression. Oxid Med Cell Longev 2018;2018:2548154. [PMID: 29955245 DOI: 10.1155/2018/2548154] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
26 Lonardo A, Mantovani A. Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. Nutr Metab Cardiovasc Dis 2021;31:2354-7. [PMID: 34154889 DOI: 10.1016/j.numecd.2021.05.019] [Reference Citation Analysis]
27 Guaraldi G, Lonardo A, Maia L, Palella FJ Jr. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. AIDS 2017;31 Suppl 2:S147-56. [PMID: 28471945 DOI: 10.1097/QAD.0000000000001483] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 6.7] [Reference Citation Analysis]
28 Cheraghpour M, Imani H, Ommi S, Alavian SM, Karimi-Shahrbabak E, Hedayati M, Yari Z, Hekmatdoost A. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. Phytother Res 2019;33:2118-25. [PMID: 31264313 DOI: 10.1002/ptr.6406] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
29 Wong S, Chan W. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol 2020;39:1-8. [DOI: 10.1007/s12664-020-01018-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
30 Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol 2019;56:385-96. [DOI: 10.1007/s00592-018-1266-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
31 Utay NS, Kitch DW, Yeh E, Fichtenbaum CJ, Lederman MM, Estes JD, Deleage C, Magyar C, Nelson SD, Klingman KL, Bastow B, Luque AE, McComsey GA, Douek DC, Currier JS, Lake JE; A5317 AIDS Clinical Trials Group Team. Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. J Infect Dis 2018;217:1770-81. [PMID: 29401318 DOI: 10.1093/infdis/jiy064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
32 El-Baz FK, Saleh DO, Abdel Jaleel GA, Hussein RA. Attenuation of Age-Related Hepatic Steatosis by Dunaliella salina Microalgae in Senescence Rats through the Regulation of Redox Status, Inflammatory Indices, and Apoptotic Biomarkers. Adv Pharmacol Pharm Sci 2020;2020:3797218. [PMID: 32420546 DOI: 10.1155/2020/3797218] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Katsiki N, Athyros VG, Mikhailidis DP. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. Journal of Diabetes and its Complications 2017;31:521-2. [DOI: 10.1016/j.jdiacomp.2016.12.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
34 Ichikawa K, Miyoshi T, Osawa K, Miki T, Toda H, Ejiri K, Yoshida M, Nanba Y, Yoshida M, Nakamura K, Morita H, Ito H. Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study. Cardiovasc Diabetol 2021;20:8. [PMID: 33413363 DOI: 10.1186/s12933-020-01192-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Ružić M, Pellicano R, Fabri M, Luzza F, Boccuto L, Brkić S, Abenavoli L. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Med 2018;60:185-91. [PMID: 29856183 DOI: 10.23736/S0031-0808.18.03472-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
36 Guerreiro GTS, Longo L, Fonseca MA, de Souza VEG, Álvares-da-Silva MR. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int 2021;15:380-91. [PMID: 33694066 DOI: 10.1007/s12072-021-10157-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Liang Y, Ye M, Hou X, Chen P, Wei L, Jiang F, Feng L, Zhong L, Liu H, Bao Y, Jia W. Development and validation of screening scores of non-alcoholic fatty liver disease in middle-aged and elderly Chinese. Diabetes Res Clin Pract 2020;169:108385. [PMID: 32853691 DOI: 10.1016/j.diabres.2020.108385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 30.0] [Reference Citation Analysis]
39 Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, Gordon SC. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther 2020;51:1149-59. [PMID: 32372515 DOI: 10.1111/apt.15679] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
40 Marinho GB, Tenório JR, Munhoz L, Andrade NS, Arita ES, Ortega KL. Detection of calcified atheromas on panoramic radiographs of cirrhotic patients. Spec Care Dentist 2021;41:164-9. [PMID: 33258155 DOI: 10.1111/scd.12551] [Reference Citation Analysis]
41 Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med 2020;9:E1278. [PMID: 32354182 DOI: 10.3390/jcm9051278] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 26.0] [Reference Citation Analysis]
42 Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, Yang MJ, Lim SG, Kim S, Cheong JY, Cho SW. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis. 2018;50:370-377. [PMID: 29398414 DOI: 10.1016/j.dld.2017.12.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
43 Badawi A, Di Giuseppe G, Gupta A, Poirier A, Arora P. Bayesian network modelling study to identify factors influencing the risk of cardiovascular disease in Canadian adults with hepatitis C virus infection. BMJ Open 2020;10:e035867. [PMID: 32371519 DOI: 10.1136/bmjopen-2019-035867] [Reference Citation Analysis]
44 Houttu V, Csader S, Nieuwdorp M, Holleboom AG, Schwab U. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Nutr 2021;8:716783. [PMID: 34368214 DOI: 10.3389/fnut.2021.716783] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Linares I, Hamar M, Selzner N, Selzner M. Steatosis in Liver Transplantation: Current Limitations and Future Strategies. Transplantation 2019;103:78-90. [DOI: 10.1097/tp.0000000000002466] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 15.5] [Reference Citation Analysis]
46 Takahashi Y. The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. Int J Mol Sci. 2017;18. [PMID: 28678199 DOI: 10.3390/ijms18071447] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 18.5] [Reference Citation Analysis]
47 Ding Y, Li G, Zhou Z, Deng T. Molecular mechanisms underlying hepatitis C virus infection-related diabetes. Metabolism 2021;121:154802. [PMID: 34090869 DOI: 10.1016/j.metabol.2021.154802] [Reference Citation Analysis]
48 Pasanta D, Tungjai M, Chancharunee S, Sajomsang W, Kothan S. Body mass index and its effects on liver fat content in overweight and obese young adults by proton magnetic resonance spectroscopy technique. World J Hepatol 2018; 10(12): 924-933 [PMID: 30631397 DOI: 10.4254/wjh.v10.i12.924] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
49 Lake JE. The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection. Curr HIV/AIDS Rep 2017;14:211-9. [PMID: 29043609 DOI: 10.1007/s11904-017-0368-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
50 Hashimoto Y, Hamaguchi M, Tanaka M, Obora A, Kojima T, Fukui M. Metabolically healthy obesity without fatty liver and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. Obes Res Clin Pract. 2018;12:4-15. [PMID: 29307656 DOI: 10.1016/j.orcp.2017.12.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
51 Sun SM, Wang YY, Zhang Q, Liu L, Meng G, Yao ZX, Wu HM, Xia Y, Bao X, Gu YQ, Wang HL, Shi HB, Xu HY, Wang X, Zhou M, Jiao HL, Jia QY, Wang BM, Niu KJ. Serum levels of immunoglobulins in an adult population and their relationship with nonalcoholic fatty liver disease: Serum immunoglobulins and NAFLD. Journal of Digestive Diseases 2018;19:498-507. [DOI: 10.1111/1751-2980.12646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Bifari F, Manfrini R, Dei Cas M, Berra C, Siano M, Zuin M, Paroni R, Folli F. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res 2018;137:219-29. [PMID: 30359962 DOI: 10.1016/j.phrs.2018.09.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
53 Lim DW, Kim H, Lee SJ, Yu GR, Kim JE, Park WH. Jwa Kum Whan Attenuates Nonalcoholic Fatty Liver Disease by Modulating Glucose Metabolism and the Insulin Signaling Pathway. Evid Based Complement Alternat Med 2019;2019:4589810. [PMID: 30881473 DOI: 10.1155/2019/4589810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Jadeja RN, Jones MA, Fromal O, Powell FL, Khurana S, Singh N, Martin PM. Loss of GPR109A/HCAR2 induces aging-associated hepatic steatosis. Aging (Albany NY) 2019;11:386-400. [PMID: 30659164 DOI: 10.18632/aging.101743] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
56 Bai L, Li H. Innate immune regulatory networks in hepatic lipid metabolism. J Mol Med (Berl). 2019;97:593-604. [PMID: 30891617 DOI: 10.1007/s00109-019-01765-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
57 Valbusa F, Bonapace S, Agnoletti D, Scala L, Grillo C, Arduini P, Turcato E, Mantovani A, Zoppini G, Arcaro G, Byrne C, Targher G. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS One 2017;12:e0173398. [PMID: 28288193 DOI: 10.1371/journal.pone.0173398] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
58 Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients 2017;9:E870. [PMID: 28805669 DOI: 10.3390/nu9080870] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
59 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]